Tradename | Company | Number | Date | Products |
---|---|---|---|---|
VIRAZOLE | Bausch Health Companies | N-018859 RX | 1985-12-31 | 1 products, RLD, RS |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepatitis c | D006526 | — | B19.2 | 3 | 26 | 22 | 40 | 26 | 116 |
Hepatitis | D006505 | HP_0012115 | K75.9 | 2 | 25 | 20 | 39 | 25 | 111 |
Hepatitis a | D006506 | EFO_0007305 | B15 | 2 | 24 | 18 | 38 | 25 | 107 |
Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 2 | 23 | 18 | 36 | 24 | 103 |
Chronic hepatitis | D006521 | — | K73.9 | — | 3 | 7 | 6 | 4 | 20 |
Hiv infections | D015658 | EFO_0000764 | B20 | — | 2 | 6 | 1 | 2 | 11 |
Coinfection | D060085 | — | — | — | — | 2 | 1 | 1 | 4 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | 1 | 1 | 2 |
Insulin resistance | D007333 | HP_0000855 | — | — | — | — | 1 | 1 | 2 |
Anemia | D000740 | HP_0001903 | D64.9 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Infections | D007239 | EFO_0000544 | — | — | 2 | 2 | — | — | 4 |
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | 2 | — | 2 | 4 |
Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | — | 3 | — | — | 3 |
Hepatitis b | D006509 | — | — | — | — | 1 | — | 1 | 2 |
Communicable diseases | D003141 | — | — | — | 1 | 1 | — | — | 2 |
Recurrence | D012008 | — | — | — | — | 1 | — | — | 1 |
Fibrosis | D005355 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 3 | 1 | — | — | — | 3 |
Treatment failure | D017211 | — | — | — | 1 | — | — | — | 1 |
Depression | D003863 | — | F33.9 | — | 1 | — | — | — | 1 |
Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | — | — | 1 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 1 | — | — | — | 1 |
Chronic hepatitis d | D019701 | — | — | — | 1 | — | — | — | 1 |
Hepatitis d | D003699 | EFO_0007304 | — | — | 1 | — | — | — | 1 |
Hepacivirus | D016174 | — | — | 1 | 1 | — | — | — | 1 |
Drug common name | Ribavirin |
INN | ribavirin |
Description | Ribavirin is a white powder and exists in two polymorphic forms. Ribavirin is a 1-ribosyltriazole that is the 1-ribofuranosyl derivative of 1,2,4-triazole-3-carboxamide. A synthetic guanosine analogue, it is an inhibitor of HCV polymerase and possesses a broad spectrum of activity against DNA and RNA viruses. It has a role as an antimetabolite, an antiviral agent, an antiinfective agent and an EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor. It is a 1-ribosyltriazole, an aromatic amide and a monocarboxylic acid amide. Ribavirin is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses. Ribavirin is incorporated into viral RNA, thereby inhibiting viral RNA synthesis, inducing viral genome mutations, and inhibiting normal viral replication. |
Classification | Small molecule |
Drug class | antivirals |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1 |
PDB | — |
CAS-ID | 36791-04-5 |
RxCUI | — |
ChEMBL ID | CHEMBL1643 |
ChEBI ID | 63580 |
PubChem CID | 37542 |
DrugBank | DB00811 |
UNII ID | 49717AWG6K (ChemIDplus, GSRS) |